Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362555 | 0.90 | P2RX7 (0.54) | P2RX7HTTL3MBTL1ALDH1A1TRPA1 | |
| SCHEMBL6357648 | 0.86 | P2RX7 (0.77) | P2RX7HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL6355213 | 0.86 | P2RX7 (0.56) | P2RX7KMT2AALDH1A1NPSR1GRM2 | |
| SCHEMBL6358951 | 0.86 | P2RX7 (0.56) | P2RX7HTTL3MBTL1ALDH1A1 | |
| SCHEMBL6362163 | 0.85 | GRM2 (0.53) | P2RX7HTTL3MBTL1ALDH1A1TRPA1 | |
| SCHEMBL6357198 | 0.81 | P2RX7 (0.51) | P2RX7HTTL3MBTL1 | |
| SCHEMBL5815008 | 0.80 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL6356231 | 0.80 | P2RX7 (0.58) | P2RX7HTTL3MBTL1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5816009 | 0.79 | P2RX7 (0.98) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL6356869 | 0.78 | P2RX7 (0.78) | P2RX7ALDH1A1TRPA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | P2RX7 448/4885HTT 761/4885L3MBTL1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.